All In Biotech

Drug Trial Radar · NCT07219017

A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants

Mass Balance Study of [14C] ABBV-1354 (Icalcaprant) in Healthy Male Subjects Following Single Oral Dose Administration

Last checked: Nov 19, 2026Latest source record: Jan 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Oct 15, 2025

Primary completion

Dec 9, 2025

Study completion Dec 9, 2025

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Oct 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is to assess the mass balance of oral ABBV-1354 in healthy adult male participants.

Conditions

  • Healthy Volunteer

Interventions

  • ABBV-1354Drug

    Oral solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 32 days
  2. Number of Participants with Abnormal Change from Baseline in Vital Sign MeasurementsTime frame: Up to approximately 15 days
  3. Change From Baseline in Electrocardiograms (ECGs)Time frame: Up to approximately 15 days
  4. Number of Participants with Abnormal Change in Physical ExaminationsTime frame: Up to approximately 15 days
  5. Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be AssessedTime frame: Up to approximately 15 days
  6. Maximum observed concentration (Cmax) of ABBV-1354Time frame: Up to approximately 15 days
  7. Time to Cmax (peak time, Tmax) of ABBV-1354Time frame: Up to approximately 15 days
  8. Terminal phase elimination half-life (t1/2) of ABBV-1354Time frame: Up to approximately 15 days
  9. Area under the plasma concentration-time curve (AUC) from time 0 to the time of the last measurable concentration (AUCt) of ABBV-1354Time frame: Up to approximately 15 days
  10. Area under the plasma concentration-time curve (AUC) from time 0 to infinite time (AUCinf) of ABBV-1354Time frame: Up to approximately 15 days
  11. Amount of ABBV-1354 excreted in the urine over the sampling period (Aeu)Time frame: Up to approximately 15 days
  12. Percent of ABBV-1354 excreted in the urineTime frame: Up to approximately 15 days
  13. Amount of ABBV-1354 excreted in the feces over the sampling period (Aeu)Time frame: Up to approximately 15 days
  14. Percent of ABBV-1354 radioactivity excreted in the fecesTime frame: Up to approximately 15 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fortrea Clinical Research Unit Inc /ID# 277011

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.